RecruitingNCT07356544

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

HER2 in Advanced NSCLC: an Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in Italy. The HEROS Study - GOIRC-01-2022

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica

Enrollment

50 participants

Start Date

Aug 12, 2025

Study Type

OBSERVATIONAL

Conditions

HER2 NSCLC (Advanced Non-small Cell Lung Cancer)

Summary

The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice. The enrolment will start in September 2024 until September 2025. A 12-months follow-up window will be performed.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking how often HER2 gene mutations occur in patients with advanced non-small cell lung cancer (NSCLC) and how doctors are treating these cases. HER2 mutations are a relatively new target in lung cancer, and this study aims to understand their prevalence and what treatments are being used in real-world practice. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) between September 2024 and September 2025 - You are enrolled in the ATLAS project (a participating cancer registry) - If applicable, your tumor has been found to have a HER2 mutation, and/or a tissue sample is available (for specific sub-groups) **You may NOT be eligible if:** - There are no specific exclusion criteria listed for this study — eligibility depends primarily on meeting the inclusion criteria above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(22)

IRCCS "Giovanni Paolo II"

Bari, BA, Italy

Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"

Meldola, FC, Italy

Arcispedale Sant'Anna

Ferrara, FE, Italy

Ospedale Policlinico San Martino

Genova, GE, Italy

Ospedale Versilia

Lido di Camaiore, LU, Italy

Azienda Sanitaria Toscana Nord - Ovest

Lucca, LU, Italy

IRCCS San Gerardo dei Tintori

Monza, MB, Italy

IRCCS Ospedale San Raffaele

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, MI, Italy

Istituto Clinico Humanitas IRRCS

Rozzano, MI, Italy

Azienda Ospedaliero - Universitaria di Modena

Modena, MO, Italy

Istituto Oncologico Veneto IRCCS

Padova, PD, Italy

Azienda Ospedaliera di Perugia

Perugia, PG, Italy

Centro di Riferimento Oncologico IRCCS di Aviano

Aviano, PN, Italy

Azienda Ospedaliera - Universitaria di Parma

Parma, PR, Italy

Fondazione IRCCS Policlinico S. Matteo

Pavia, PV, Italy

Azienda Ospedaliero - Universitaria di Reggio Emilia

Reggio Emilia, RE, Italy

Istituto Nazionale dei Tumori Regina Elena IRCCS - IFO

Roma, RM, Italy

Azienda Ospedaliera San Camillo Forlanini

Roma, RM, Italy

AOU San Luigi Orbassano

Orbassano, TO, Italy

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)

Udine, UD, Italy

Azienda Ospedaliera Universitaria Integrata Verona

Verona, VR, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07356544

Related Trials

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT0670607641 locations

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NCT070850917 locations

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT069927391 location

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT0625387148 locations

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

NCT075282741 location